{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:03:44Z","timestamp":1794441824323,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Understanding the mechanisms underlying chemoresistance is critical for improving cancer therapies. SIN1 plays a pivotal role in maintaining mTORC2 integrity and activation, which regulates key cellular processes. In this study, we demonstrate that elevated SIN1 expression in pancreatic ductal adenocarcinoma (PDAC) correlates with poor patient survival outcomes. Conversely, SIN1 deletion reduces tumor growth and enhances PDAC sensitivity to chemotherapy. We identify USP33 as a bona fide deubiquitanase of SIN1, essential for its stabilization in PDAC. This stabilization promotes chemoresistance by activating the mTORC2-AKT pathway. Additionally, we show that CDK1 directly phosphorylates USP33, enhancing its deubiquitinase activity toward SIN1 and driving PDAC progression. Inhibition or genetic ablation of CDK1 significantly diminishes these malignant phenotypes. Furthermore, we observe a strong positive correlation between CDK1, USP33, and SIN1 expressions in PDAC tissues. Our results provide compelling preclinical evidence that targeting the CDK1\u2013USP33 axis may offer a promising therapeutic strategy to destabilize SIN1 and overcome chemoresistance in PDAC and potentially other aggressive cancers.<\/jats:p>","DOI":"10.1038\/s41419-025-07869-6","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T07:31:07Z","timestamp":1753169467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phosphorylation of USP33 by CDK1 stabilizes the mTORC2 component SIN1"],"prefix":"10.1038","volume":"16","author":[{"given":"Yalei","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caishi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0859-3923","authenticated-orcid":false,"given":"Tongzheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"7869_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","volume":"22","author":"AA Connor","year":"2022","unstructured":"Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2022;22:131\u201342.","journal-title":"Nat Rev Cancer"},{"key":"7869_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum Y, Na\u2019ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat 2015;23:55\u201368.","journal-title":"Drug Resist Updat"},{"key":"7869_CR3","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-19-0960","volume":"79","author":"S Dalin","year":"2019","unstructured":"Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, et al. Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. Cancer Res. 2019;79:5723\u201333.","journal-title":"Cancer Res"},{"key":"7869_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960\u201376.","journal-title":"Cell"},{"key":"7869_CR5","doi-asserted-by":"publisher","first-page":"eabc1251","DOI":"10.1126\/sciadv.abc1251","volume":"6","author":"A Scaiola","year":"2020","unstructured":"Scaiola A, Mangia F, Imseng S, Boehringer D, Berneiser K, Shimobayashi M, et al. The 3.2-A resolution structure of human mTORC2. Sci Adv. 2020;6:eabc1251.","journal-title":"Sci Adv"},{"key":"7869_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7869_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14430-w","volume":"11","author":"C Martinez Calejman","year":"2020","unstructured":"Martinez Calejman C, Trefely S, Entwisle SW, Luciano A, Jung SM, Hsiao W, et al. mTORC2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis. Nat Commun. 2020;11:575.","journal-title":"Nat Commun"},{"key":"7869_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/2159-8290.CD-15-1125","volume":"5","author":"HX Yuan","year":"2015","unstructured":"Yuan HX, Guan KL. The SIN1-PH domain connects mTORC2 to PI3K. Cancer Discov. 2015;5:1127\u20139.","journal-title":"Cancer Discov"},{"key":"7869_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/gutjnl-2018-316822","volume":"68","author":"JR Conway","year":"2019","unstructured":"Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut. 2019;68:742\u201358.","journal-title":"Gut"},{"key":"7869_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/cncr.28023","volume":"119","author":"J Xu","year":"2013","unstructured":"Xu J, Li X, Yang H, Chang R, Kong C, Yang L. SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial\u2013mesenchymal transition. Cancer. 2013;119:2247\u201357.","journal-title":"Cancer"},{"key":"7869_CR11","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1038\/onc.2017.228","volume":"36","author":"Q Wang","year":"2017","unstructured":"Wang Q, Zhu J, Wang YW, Dai Y, Wang YL, Wang C, et al. Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma. Oncogene. 2017;36:6225\u201334.","journal-title":"Oncogene"},{"key":"7869_CR12","doi-asserted-by":"crossref","unstructured":"Wang D, Wu P, Wang H, Zhu L, Zhao W, Lu Y. SIN1 promotes the proliferation and migration of breast cancer cells by Akt activation. Biosci Rep 2016;36:e00424.","DOI":"10.1042\/BSR20160192"},{"key":"7869_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13923","volume":"8","author":"T Liu","year":"2017","unstructured":"Liu T, Yu J, Deng M, Yin Y, Zhang H, Luo K, et al. CDK4\/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun. 2017;8:13923.","journal-title":"Nat Commun"},{"key":"7869_CR14","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1021\/jacs.9b12116","volume":"142","author":"N Ma","year":"2020","unstructured":"Ma N, Hu J, Zhang ZM, Liu W, Huang M, Fan Y, et al. 2H-azirine-based reagents for chemoselective bioconjugation at carboxyl residues inside live cells. J Am Chem Soc. 2020;142:6051\u20139.","journal-title":"J Am Chem Soc"},{"key":"7869_CR15","doi-asserted-by":"crossref","unstructured":"Wen Y, Wang H, Yang X, Zhu Y, Li M, Ma X, et al. Pharmacological targeting of casein kinase 1\u03b4 suppresses oncogenic NRAS-driven melanoma. Nat Commun 2024;15:10088.","DOI":"10.1038\/s41467-024-54140-1"},{"key":"7869_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.apsb.2022.05.019","volume":"13","author":"M Sun","year":"2023","unstructured":"Sun M, Li L, Niu Y, Wang Y, Yan Q, Xie F, et al. PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD\/ENO1 mediated cell metabolism. Acta Pharm Sin B. 2023;13:157\u201373.","journal-title":"Acta Pharm Sin B"},{"key":"7869_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41418-021-00828-6","volume":"29","author":"C Huang","year":"2022","unstructured":"Huang C, Du R, Jia X, Liu K, Qiao Y, Wu Q, et al. CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating beta-catenin\/MEK-ERK signaling pathway. Cell Death Differ. 2022;29:14\u201327.","journal-title":"Cell Death Differ"},{"key":"7869_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112445","volume":"42","author":"L Zhou","year":"2023","unstructured":"Zhou L, Yao N, Yang L, Liu K, Qiao Y, Huang C, et al. DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90beta. Cell Rep. 2023;42:112445.","journal-title":"Cell Rep"},{"key":"7869_CR19","volume":"5","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innov (Camb (Mass)). 2024;5:100625.","journal-title":"Innov (Camb (Mass))"},{"key":"7869_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.celrep.2015.07.016","volume":"12","author":"G Yang","year":"2015","unstructured":"Yang G, Murashige DS, Humphrey SJ, James DE. A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. Cell Rep. 2015;12:937\u201343.","journal-title":"Cell Rep"},{"key":"7869_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/nsr\/nwz171","volume":"6","author":"C Ruan","year":"2019","unstructured":"Ruan C, Ouyang X, Liu H, Li S, Jin J, Tang W, et al. Sin1-mediated mTOR signaling in cell growth, metabolism and immune response. Natl Sci Rev. 2019;6:1149\u201362.","journal-title":"Natl Sci Rev"},{"key":"7869_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80\u201391.","journal-title":"Semin Cancer Biol"},{"key":"7869_CR23","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1158\/0008-5472.CAN-18-0330","volume":"78","author":"D Ravindran Menon","year":"2018","unstructured":"Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, et al. CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma. Cancer Res. 2018;78:6561\u201374.","journal-title":"Cancer Res"},{"key":"7869_CR24","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.7150\/thno.25487","volume":"8","author":"CX Wu","year":"2018","unstructured":"Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, et al. Blocking CDK1\/PDK1\/\u03b2-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 2018;8:3737\u201350.","journal-title":"Theranostics"},{"key":"7869_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.molcel.2020.03.010","volume":"78","author":"W Michowski","year":"2020","unstructured":"Michowski W, Chick JM, Chu C, Kolodziejczyk A, Wang Y, Suski JM, et al. Cdk1 controls global epigenetic landscape in embryonic stem cells. Mol Cell. 2020;78:459\u201376.e13.","journal-title":"Mol Cell"},{"key":"7869_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep07929","volume":"5","author":"K Suzuki","year":"2015","unstructured":"Suzuki K, Sako K, Akiyama K, Isoda M, Senoo C, Nakajo N, et al. Identification of non-Ser\/Thr-Pro consensus motifs for Cdk1 and their roles in mitotic regulation of C2H2 zinc finger proteins and Ect2. Sci Rep. 2015;5:7929.","journal-title":"Sci Rep"},{"key":"7869_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1158\/0008-5472.CAN-15-0671","volume":"76","author":"T Liu","year":"2016","unstructured":"Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu N, et al. HEATR1 negatively regulates Akt to help sensitize pancreatic cancer cells to chemotherapy. Cancer Res. 2016;76:572\u201381.","journal-title":"Cancer Res"},{"key":"7869_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-021-06450-x","volume":"191","author":"N Turner","year":"2022","unstructured":"Turner N, Dent RA, O\u2019Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, et al. Ipatasertib plus paclitaxel for PIK3CA\/AKT1\/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022;191:565\u201376.","journal-title":"Breast Cancer Res Treat"},{"key":"7869_CR29","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1021\/acs.jmedchem.4c00075","volume":"67","author":"KA Pervanidis","year":"2024","unstructured":"Pervanidis KA, D\u2019Angelo GD, Weisner J, Brandherm S, Rauh D. Akt inhibitor advancements: from capivasertib approval to covalent-allosteric promises. J Med Chem. 2024;67:6052\u201363.","journal-title":"J Med Chem"},{"key":"7869_CR30","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/ncb2860","volume":"15","author":"P Liu","year":"2013","unstructured":"Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol. 2013;15:1340\u201350.","journal-title":"Nat Cell Biol"},{"key":"7869_CR31","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-15-0460","volume":"5","author":"P Liu","year":"2015","unstructured":"Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, et al. PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. 2015;5:1194\u2013209.","journal-title":"Cancer Discov"},{"key":"7869_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","volume":"12","author":"H Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12:71.","journal-title":"J Hematol Oncol"},{"key":"7869_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1464","volume":"13","author":"E Ezine","year":"2023","unstructured":"Ezine E, Lebbe C, Dumaz N. Unmasking the tumourigenic role of SIN1\/MAPKAP1 in the mTOR complex 2. Clin Transl Med. 2023;13:e1464.","journal-title":"Clin Transl Med"},{"key":"7869_CR34","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41419-024-07035-4","volume":"15","author":"C Xiang","year":"2024","unstructured":"Xiang C, Chen L, Zhu S, Chen Y, Huang H, Yang C, et al. CRLF1 bridges AKT and mTORC2 through SIN1 to inhibit pyroptosis and enhance chemo-resistance in ovarian cancer. Cell Death Dis. 2024;15:662.","journal-title":"Cell Death Dis"},{"key":"7869_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021109187","volume":"41","author":"A Zhang","year":"2022","unstructured":"Zhang A, Huang Z, Tao W, Zhai K, Wu Q, Rich JN, et al. USP33 deubiquitinates and stabilizes HIF-2alpha to promote hypoxia response in glioma stem cells. EMBO J. 2022;41:e109187.","journal-title":"EMBO J"},{"key":"7869_CR36","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1038\/s41388-024-03151-9","volume":"43","author":"J Chen","year":"2024","unstructured":"Chen J, Shan W, Jia Q, Chen Y, Jiang W, Tian Y, et al. USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2. Oncogene. 2024;43:3170\u201383.","journal-title":"Oncogene"},{"key":"7869_CR37","doi-asserted-by":"crossref","unstructured":"Zhu Y, Chen Z, Niu K, Li M, Deng Y, Zhang J, et al. USP33 regulates DNA damage response and carcinogenesis through deubiquitylating and stabilising p53. Cell Prolif. 2024;58:e13793.","DOI":"10.1111\/cpr.13793"},{"key":"7869_CR38","doi-asserted-by":"publisher","first-page":"14530","DOI":"10.1073\/pnas.0801262106","volume":"106","author":"J Yuasa-Kawada","year":"2009","unstructured":"Yuasa-Kawada J, Kinoshita-Kawada M, Rao Y, Wu JY. Deubiquitinating enzyme USP33\/VDU1 is required for Slit signaling in inhibiting breast cancer cell migration. Proc Natl Acad Sci USA. 2009;106:14530\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7869_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118316","volume":"261","author":"Q Gan","year":"2020","unstructured":"Gan Q, Shao J, Cao Y, Lei J, Xie P, Ge J, et al. USP33 regulates c-Met expression by deubiquitinating SP1 to facilitate metastasis in hepatocellular carcinoma. Life Sci. 2020;261:118316.","journal-title":"Life Sci"},{"key":"7869_CR40","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41418-019-0473-8","volume":"27","author":"F Guo","year":"2020","unstructured":"Guo F, Zhang C, Wang F, Zhang W, Shi X, Zhu Y, et al. Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer. Cell Death Differ. 2020;27:1938\u201351.","journal-title":"Cell Death Differ"},{"key":"7869_CR41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41419-023-05871-4","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Xu J, Shen B, Xu J, Jiang J. USP33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2\/TGF\u03b2 signaling pathway. Cell Death Dis. 2023;14:362.","journal-title":"Cell Death Dis"},{"key":"7869_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2017.05.011","volume":"356","author":"Q Cheng","year":"2017","unstructured":"Cheng Q, Yuan Y, Li L, Guo T, Miao Y, Ren Y, et al. Deubiquitinase USP33 is negatively regulated by \u03b2-TrCP through ubiquitin-dependent proteolysis. Exp Cell Res. 2017;356:1\u20137.","journal-title":"Exp Cell Res"},{"key":"7869_CR43","doi-asserted-by":"publisher","first-page":"19789","DOI":"10.1074\/jbc.M114.569392","volume":"289","author":"NC Chan","year":"2014","unstructured":"Chan NC, den Besten W, Sweredoski MJ, Hess S, Deshaies RJ, Chan DC. Degradation of the deubiquitinating enzyme USP33 is mediated by p97 and the ubiquitin ligase HERC2. J Biol Chem. 2014;289:19789\u201398.","journal-title":"J Biol Chem"},{"key":"7869_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"7869_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153\u201366.","journal-title":"Nat Rev Cancer"},{"key":"7869_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"Q Wang","year":"2023","unstructured":"Wang Q, Bode AM, Zhang T. Targeting CDK1 in cancer: mechanisms and implications. NPJ Precis Oncol. 2023;7:58.","journal-title":"NPJ Precis Oncol"},{"key":"7869_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13578-023-01118-z","volume":"13","author":"X Xu","year":"2023","unstructured":"Xu X, Ding Y, Jin J, Xu C, Hu W, Wu S, et al. Post-translational modification of CDK1-STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties. Cell Biosci. 2023;13:176.","journal-title":"Cell Biosci"},{"key":"7869_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114704","volume":"243","author":"L Akl","year":"2022","unstructured":"Akl L, Abd El-Hafeez AA, Ibrahim TM, Salem R, Marzouk HMM, El-Domany RA, et al. Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer. Eur J Med Chem. 2022;243:114704.","journal-title":"Eur J Med Chem"},{"key":"7869_CR49","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1080\/15384101.2018.1491236","volume":"17","author":"R Prevo","year":"2018","unstructured":"Prevo R, Pirovano G, Puliyadi R, Herbert KJ, Rodriguez-Berriguete G, O\u2019Docherty A, et al. CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner. Cell Cycle (Georget, TX). 2018;17:1513\u201323.","journal-title":"Cell Cycle (Georget, TX)"},{"key":"7869_CR50","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1158\/1078-0432.CCR-20-4781","volume":"27","author":"A Kazi","year":"2021","unstructured":"Kazi A, Chen L, Xiang S, Vangipurapu R, Yang H, Beato F, et al. Global phosphoproteomics reveal CDK suppression as a vulnerability to KRas addiction in pancreatic cancer. Clin Cancer Res 2021;27:4012\u201324.","journal-title":"Clin Cancer Res"},{"key":"7869_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110531","volume":"200","author":"S Van Matre","year":"2024","unstructured":"Van Matre S, Huq S, Akana L, Eldridge DE, Zuniga O, Rodrigues H, et al. Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1. Radiother Oncol. 2024;200:110531.","journal-title":"Radiother Oncol"},{"key":"7869_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11161","volume":"7","author":"G Banyai","year":"2016","unstructured":"Banyai G, Ba\u00efdi F, Coudreuse D, Szilagyi Z. Cdk1 activity acts as a quantitative platform for coordinating cell cycle progression with periodic transcription. Nat Commun. 2016;7:11161.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07869-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07869-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07869-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:20:45Z","timestamp":1757272845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07869-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7869"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07869-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"PDAC pathological tissue sections were obtained from the tissue bank at The First Affiliated Hospital of Jinan University in accordance with the approval document of the Institutional Medical Ethics Committee (Ethics Approval License: JNUKY-2022-097). All animal experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of JINAN University (Ethics Approval License: 20230205-08).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"543"}}